| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/31/2011 | CA2775124A1 Combination |
| 03/31/2011 | CA2775092A1 Compositions and methods for silencing genes expressed in cancer |
| 03/31/2011 | CA2774973A1 Peptidomimetic macrocycles |
| 03/31/2011 | CA2774946A1 Identification of antigenic peptides from multiple myeloma cells |
| 03/31/2011 | CA2774836A1 Antagonists of dsg2 for treatment of cancer |
| 03/31/2011 | CA2774807A1 Benzoxepin pi3k inhibitor compounds and methods of use |
| 03/31/2011 | CA2774731A1 Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof |
| 03/31/2011 | CA2774647A1 Substituted amide compound |
| 03/31/2011 | CA2774332A1 Piperidine and piperazine derivatives as smo antagonists |
| 03/31/2011 | CA2773978A1 Methods of treating inflammation |
| 03/31/2011 | CA2773306A1 Process |
| 03/31/2011 | CA2773305A1 Crystalline methylthioninium chloride hydrates |
| 03/31/2011 | CA2772691A1 Benzoxazepin pi3k inhibitor compounds and methods of use |
| 03/31/2011 | CA2770278A1 Pyrazoline dione derivatives as nadph oxidase inhibitors |
| 03/30/2011 | EP2302039A1 Virus-like particles comprising HML-2 gag polypeptide |
| 03/30/2011 | EP2302038A1 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
| 03/30/2011 | EP2301971A1 Antibodies that bind both BCMA and TACI |
| 03/30/2011 | EP2301970A1 Human antibodies that bind human IL-12 and methods for producing |
| 03/30/2011 | EP2301967A2 Single domain antibodies for nasal administration |
| 03/30/2011 | EP2301952A2 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 03/30/2011 | EP2301940A1 Epothilone derivatives |
| 03/30/2011 | EP2301939A1 Enzyme inhibitors |
| 03/30/2011 | EP2301930A1 Thrombin receptor antagonists |
| 03/30/2011 | EP2301915A1 7-(diethylamino)methyl substituted tetracycline having target therapeutic activities |
| 03/30/2011 | EP2301580A1 Anti-VEGF antibodies |
| 03/30/2011 | EP2301579A1 Therapeutic method for reducing angiogenesis |
| 03/30/2011 | EP2301576A1 Therapeutic use of Anti-CS1 Antibodies |
| 03/30/2011 | EP2301575A1 Methods of therapy for solid tumors expressing the CD40 cell-surface antigen |
| 03/30/2011 | EP2301570A1 Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated and conjugated antibodies, antibody combinations and fusion proteins |
| 03/30/2011 | EP2301565A1 Use of proteasome inhibitors for the treatment of viral infections |
| 03/30/2011 | EP2301563A2 HSP20 peptides |
| 03/30/2011 | EP2301556A1 Co-Administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer |
| 03/30/2011 | EP2301551A1 Use of alkyl phosphocholines in combination with antitumor medicaments |
| 03/30/2011 | EP2301550A1 Tetracycline compounds having target therapeutic activities |
| 03/30/2011 | EP2301546A1 Treatment of metastasized tumors |
| 03/30/2011 | EP2301538A1 Compounds for nonsense suppression, and methods for their use |
| 03/30/2011 | EP2301535A1 Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy |
| 03/30/2011 | EP2301534A1 Amino-methyl substituted tetracycline compounds |
| 03/30/2011 | EP2301533A1 Wortmannin Analogs and Method of Using Same |
| 03/30/2011 | EP2301531A2 Combinations and modes of administration of therapeutic agents and combination therapy |
| 03/30/2011 | EP2301529A1 Hydroxymethylbutyrate compositions and uses thereof |
| 03/30/2011 | EP2301528A1 Use of FTS for treating malignant disorders |
| 03/30/2011 | EP2301349A2 Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer |
| 03/30/2011 | EP2300608A2 Methods to treat solid tumors |
| 03/30/2011 | EP2300483A1 Triazine compounds as p13 kinase and mtor inhibitors |
| 03/30/2011 | EP2300482A1 Annellated 4- (indazolyl) -1,4-dihydropyridine derivatives and methods of use thereof |
| 03/30/2011 | EP2300475A1 Diazacarbazoles and methods of use |
| 03/30/2011 | EP2300465A1 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases |
| 03/30/2011 | EP2300460A1 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 03/30/2011 | EP2300457A1 Substituted pyrroles and methods of use |
| 03/30/2011 | EP2300455A2 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl) - imidazo [1, 2-b] [1, 2, 4] triazin-2-yl] benzamide and processes related to preparing the same |
| 03/30/2011 | EP2300441A1 Crystalline salt forms of antifolate compounds and methods of manufacturing thereof |
| 03/30/2011 | EP2300437A1 Benzpyrazol derivatives as inhibitors of pi3 kinases |
| 03/30/2011 | EP2300436A1 Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs |
| 03/30/2011 | EP2300434A1 Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors |
| 03/30/2011 | EP2300057A2 18f-labelled three-and four-carbon acids for pet imaging |
| 03/30/2011 | EP2300055A1 Anticancer combination therapy including triciribine |
| 03/30/2011 | EP2300054A2 Inorganic nanoparticles of high density to destroy cells in-vivo |
| 03/30/2011 | EP2300049A1 Use of a dead-box rna helicase for inducing cytokine production |
| 03/30/2011 | EP2300045A1 Treatment of metastatic tumors |
| 03/30/2011 | EP2300041A2 Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants |
| 03/30/2011 | EP2300040A2 Methods and compositions for prostate cancer immunotherapy |
| 03/30/2011 | EP2300030A2 Rice bran extracts and methods of use thereof |
| 03/30/2011 | EP2300029A2 Rice bran extracts for inflammation and methods of use thereof |
| 03/30/2011 | EP2300023A2 Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| 03/30/2011 | EP2300011A1 Therapeutic methods and compounds |
| 03/30/2011 | EP2300004A2 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof |
| 03/30/2011 | EP2299999A1 Stat3 inhibitors |
| 03/30/2011 | EP2299996A1 5-lipoxygenase inhibitors |
| 03/30/2011 | EP2299971A1 Solid pharmaceutical formulations comprising bibw 2992 |
| 03/30/2011 | EP2176259B1 Fused imidazoles for cancer treatment |
| 03/30/2011 | EP2125736B1 Substituted acetophenones useful as pde4 inhibitors |
| 03/30/2011 | EP2027156B9 Hepatocyte growth factor (hgf) binding proteins |
| 03/30/2011 | EP1951739B1 An improved process for the isolation of arjunic acid from the bark of the tree terminalia arjuna and the use of this compound in the treatment of cancer |
| 03/30/2011 | EP1856066B1 Anti-cancer and anti-microbial oxazolidinones and analogues |
| 03/30/2011 | EP1775289B1 Novel imidazolidine derivatives |
| 03/30/2011 | EP1558586B1 Inhibitors of akt activity |
| 03/30/2011 | EP1503773B1 Hepatoprotective activity of 2 -p-hydroxybenzoylmussaenosidic acid |
| 03/30/2011 | EP1500698B1 Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| 03/30/2011 | EP1355658B1 Anti HER3 antibody for diagnosis, prevention and treatment of hyperproliferative diseases |
| 03/30/2011 | EP1277738B1 Condensed heteroaryl derivatives |
| 03/30/2011 | EP1053023B2 Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
| 03/30/2011 | CN1966500B Quinoxaline derivative, preparation method and uses |
| 03/30/2011 | CN1900046B Kaurane diterpine compound and its preparing method and use |
| 03/30/2011 | CN1489583B Novel physiologically active substance |
| 03/30/2011 | CN101998951A Acylthiourea compound or salt thereof, and use thereof |
| 03/30/2011 | CN101998865A Combined treatment with an EGFR kinase inhibitor and an inhibitor of C-KIT |
| 03/30/2011 | CN101998861A Method of treating prostate cancer with the gnrh antagonist degarelix |
| 03/30/2011 | CN101998857A Wet granulation using a water sequestering agent |
| 03/30/2011 | CN101998853A Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators |
| 03/30/2011 | CN101998852A Novel estrogen receptor ligands |
| 03/30/2011 | CN101993892A Eukaryotic expression vector for expressing shRNA (short hairpin Ribonucleic Acid) in manner of targeting in cancer cells |
| 03/30/2011 | CN101993877A Human miR-296-5p antisense nucleic acid and application thereof |
| 03/30/2011 | CN101993875A ShRNA of human CSAG1 genes and application |
| 03/30/2011 | CN101993874A ShRNA of human Cxorf41 gene and application thereof |
| 03/30/2011 | CN101993873A shRNA of human ZCCHC13 gene and application thereof |
| 03/30/2011 | CN101993872A shRNA of human MAGEA9 gene and application thereof |
| 03/30/2011 | CN101993871A shRNA of human DUSP21 gene and application thereof |
| 03/30/2011 | CN101993869A Relevant experimental technique of epiphyte secondary metabolism function reformation and application thereof |
| 03/30/2011 | CN101993493A Anti-tumor monoclonal antibody and preparation method and application thereof |